Unsubscribe | drugdiscoveryanddevelopment.co.uk

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials

GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data

New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...

Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM

Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

Unsubscribe from the DDD Newsletter

Menu